research Ritlecitinib: Efficacy of a Novel Therapy for Severe Alopecia Areata in Patients Aged 12 Years and Older
Ritlecitinib is effective and safe for treating severe alopecia areata in people aged 12 and older.
Search
for
Sort by
Research
930-960 / 1000+ results
research Topical Application of the Synthetic Triterpenoid RTA 408 Protects Mice from Radiation-Induced Dermatitis
RTA 408 cream protects mice from radiation skin damage.
research Overcoming genetic drivers in alopecia areata: hair regrowth in a patient with AIRE gene mutation (autoimmune polyendocrinopathy–candidiasis–ectodermal dystrophy, APECED syndrome) treated with ruxolitinib
Ruxolitinib helped a patient with alopecia areata regrow hair.
research The Relative Efficacy and Safety of Monotherapies for Alopecia Areata: A Network Meta‐Analysis Study
Janus kinase inhibitors are effective and safe for treating Alopecia Areata.
research Role of janus kinase inhibitors in the treatment of alopecia areata
Janus kinase inhibitors show promise in treating alopecia areata but need better topical formulations.
research Severe Psoriasis Leading to Scarring Alopecia of the Scalp Responding to Biologic Therapy
Bimekizumab can improve scarring alopecia in severe psoriasis.
research 008 Stratifying alopecia areata systemic treatments: Tailored approaches to disease severity
Tailored treatments for alopecia areata show promising results, with pulse steroids effective for mild cases and Ritlecitinib, Dupilumab, or methotrexate and prednisone effective for severe cases.
research Weight Gain and Hair Loss during Anti-TNF Therapy
Anti-TNF therapy can cause weight gain and hair loss, leading some patients to stop treatment.
research AB0442 Real-life experience with belimumab in systemic lupus erythematosus (SLE): control of disease activity and flares in a multicenter cohort
Belimumab effectively controls SLE disease activity and reduces steroid use.
research Switching JAK inhibitors: evaluating baricitinib’s effectiveness in alopecia areata after tofacitinib failure
Baricitinib is a safe and effective alternative for alopecia areata patients who do not respond to tofacitinib.
research Immunosuppressive therapy in autoimmune disease — A review
Immunosuppressive therapy helps manage autoimmune diseases but carries risks like infection and potential for malignancy.
research 183 PD-1 regulatory network is upregulated in contact immunotherapy during alopecia areata treatment
Contact immunotherapy can change immune responses in alopecia areata, suggesting new treatment targets.
research Polymer conjugated retinoids for controlled transdermal delivery
A new method allows for controlled, long-lasting delivery of retinoic acid through the skin with fewer side effects.
research Intralesional betamethasone versus triamcinolone acetonide in the treatment of localized alopecia areata: a within-patient randomized controlled trial
Triamcinolone acetonide is slightly more effective than betamethasone for hair regrowth in localized alopecia areata.
research Comparative study between topical application of triamcinolone acetonide after fractional carbon dioxide laser versus microneedling in the treatment of resistant alopecia areata
Both treatments for resistant alopecia areata were equally effective.
research 0935 Unravelling the role of JAK3/TEC kinase signalling with ritlecitinib in alopecia areata lesional skin and alopecia areata-induced human hair follicles ex vivo
Ritlecitinib reduces alopecia areata symptoms by blocking JAK3/TEC signaling and T-cell activity.
research Tacrolimus in Solution as an Option to Inflammatory Conditions of the Scalp
Tacrolimus solution is effective and well-tolerated for treating inflammatory scalp conditions.
research Infliximab as First‐Line Therapy in Severe Pediatric Crohn Disease
Early use of infliximab in severe pediatric Crohn's disease can lead to significant improvement and remission.
research Intralesional Triamcinolone Acetonide in the Management of Acne Keloidalis Nuchae
Intralesional triamcinolone acetonide effectively treats acne keloidalis nuchae with minimal side effects.
research The comparison of treatment with clobetasol propionate 0.05% and topical pimecrolimus 1% treatment in the treatment of alopecia areata
Clobetasol and pimecrolimus are similarly effective for alopecia areata, but pimecrolimus has fewer side effects and is preferred for long-term use.
research Asynchronous telemedicine for isotretinoin management: A direct care pilot
Asynchronous telemedicine for acne treatment is effective and improves access and productivity.
research Identification of neprilysin as a potential target of arteannuin using computational drug repositioning
Arteannuin might work against cancer and Alzheimer's by targeting neprilysin.
research Topical JAK Inhibitors for the Treatment of Alopecia Areata and Vitiligo
Topical JAK inhibitors can effectively treat alopecia areata and vitiligo by modulating immune responses.
research P164 Cutaneous toxicities occurring during amivantamab treatment: the experience of a single large specialist institution
Amivantamab treatment often causes skin issues that can affect quality of life and treatment continuation.
research Oral tofacitinib for recalcitrant lichen planus pigmentosus: A hospital-based retrospective study
Tofacitinib effectively improves lichen planus pigmentosus symptoms.
research Successful Treatment of Severe Alopecia Areata With Oral or Topical Tofacitinib.
Oral and topical tofacitinib can help regrow hair in people with severe alopecia areata.
research Clinical Evaluation of Intralesional Triamcinolone
Different doses of triamcinolone injections work equally well for skin conditions.
research Evaluation of methotrexate-loaded surfactants, ceramides and cholesterol-based lamellar phases as a topical treatment for psoriasis
Methotrexate-loaded formulations showed promise for psoriasis treatment but need careful evaluation.
research The role of B cell-activating factor system in autoimmune diseases: mechanisms, disease implications, and therapeutic advances
BAFF-targeted therapies can reduce autoimmune disease activity, but more research is needed for precise treatments.
research Moving Beyond Boundaries: Utilization of Longitudinal Exposure–Response Model for Bounded Outcome Score to Inform Decision Making in the Accelerated Drug Development Paradigm
A 50 mg daily dose of ritlecitinib is effective for alopecia areata, with temporary treatment breaks up to 6 weeks not affecting results.